AvH: 15%

Key figures

Management

Pictures

OncoDNA

Beneficial interest AvH: 15%
AvH Contact: John-Eric Bertrand
www.oncodna.com

OncoDNA supports the decision-making with regard to the treatment of patients suffering from advanced (metastatic) cancer. Personalised treatment is important, as each cancer is different for each patient. OncoDNA helps the oncologist to choose the best medical treatment and to better monitor the evolution of the cancer, and in particular whether or not the disease responds to the treatment.

Information from the 2017 annual report

Since AvH became a shareholder in 2016, the OncoDNA team has expanded from about 20 to around 65 employees. OncoDNA works together with more than 3,000 oncologists and about one hundred institutions in more than 50 countries.

In 2017, OncoDNA officially launched its IT solution OncoKDM, a SaaS (Software as a Service) solution. Laboratories around the world can use KDM (Knowledge Driven Medicine) to send their data to the platform of OncoKDM, with a view to obtain a remote interpretation, and for the creation of a detailed report for their oncologists. This report is shared on OncoSHARE, the innovative platform for communication, sharing and networking with more than 14,000 users (oncologists, patients and relatives of the patients). With the support of the Walloon Region, OncoDNA has launched the ambitious Moncodaneum project. Worldwide, 20 large centres for cancer treatment will be connected to OncoKDM, so that they can access the databases and expertise of OncoDNA. Several important partnerships have already become a fact or will soon be established.

In 2017, OncoDNA also launched two new analyses in the market, Onco- STRAT&GO and OncoSELECT. The first enables the analysis of tumours on the basis of a biopsy of the primary tumour or of a metastasis, and also on the basis of the blood. The second is an exclusively blood-based analysis solution for lung cancer, breast cancer and colon cancer, which indicates whether the patient is eligible for certain treatments.

2017 was characterised in particular by the initial explorations of various insurers at a global level, who are beginning to enable the repayment of the OncoDNA analyses. This early stage of repayment is the result of ongoing clinical demonstration studies (the ARCHE project, with the support of the Walloon Region), but is also thanks to publications, and in particular to the feedback from oncologists who are aware of the usefulness of this approach. The first partnerships with major pharmaceutical actors were also launched in 2017.

In 2018, the focus will be on the accreditation of OncoDNA analyses for their reimbursement by insurances, health insurance funds or the social security. Another key development priority is the roll-out of OncoKDM in the major cancer centres.

Open